Our Take
The FDA blinked, but didn't clarify the rule—leaving other wearable makers guessing whether their wellness claims will hold up under the next review.
Why it matters
Wearable makers live in a regulatory gray zone between medical devices (which need FDA clearance) and wellness tools (which don't). This quiet settlement sets no precedent and offers no protection to competitors.
Do this week
Product teams: audit your wearable's health claims against the FDA's July 2025 warning to Whoop and document the wellness-only framing before your next product update.
FDA reverses enforcement stance without clarifying its standard
The FDA informed Whoop last week that it would not pursue further enforcement action over the company's Blood Pressure Insights feature. This reversal follows Whoop's decision to modify the feature after the agency issued a warning in July 2025.
In that initial warning, the FDA stated that Whoop's blood pressure reading tool was a medical device because it was "intended to provide a measurement or estimation of a user's blood pressure, which is inherently associated with the diagnosis of hypo- and hypertension." Medical devices require FDA clearance before launch. Whoop disagreed publicly, arguing the feature was designed for wellness monitoring, not diagnosis or treatment, and therefore fell outside FDA jurisdiction.
The company appears to have made changes to satisfy the agency, but neither Whoop nor the FDA has disclosed what those changes were. CEO Will Ahmed's initial pushback was direct: "We won't let regulatory overreach dictate how people access their own health data." The quiet settlement offers no statement of what constitutes acceptable wellness language versus prohibited medical claims.
The FDA's guidance remains ambiguous and poses risks to users
This outcome is a win for Whoop but not a win for the industry or consumers. The FDA neither clarified its enforcement standard nor published revised guidance. Other wearable makers cannot rely on this settlement as legal cover for similar features.
The agency's broader wellness guidance, which the STAT article notes remains unclear, creates a moving target. A feature labeled "wellness" today might be reclassified as a medical device tomorrow if the FDA interprets the same claims differently in another enforcement action. Companies have no transparent criteria for predicting which side of the line their products will fall on.
Users also lose. A blood pressure reading that the FDA once considered medically significant enough to require clearance is now released with no agency review. That doesn't necessarily mean it's inaccurate, but it does mean no third party vetted the algorithm's accuracy, the conditions under which it works, or the risks of misuse (e.g., a user delaying medical care based on a false reading).
Treat this settlement as a data point, not a precedent
Product teams at wearable companies should document every health claim in their feature specifications and tie each claim explicitly to wellness language: "supports awareness of" rather than "measures" or "diagnoses." This won't guarantee FDA acceptance, but it creates a paper trail if enforcement comes later.
Legal teams should monitor the FDA's next few enforcement actions against wearable makers to see if a pattern emerges. One quiet reversal is not a policy shift. The agency may enforce more aggressively against the next company, or it may signal clearer rules in formal guidance. Until then, assume the standard is context-dependent and reactive, not predictable.